Table 1.
Baseline characteristics of patients included in this post-hoc analysis of the Sharafkhaneh et al. study [16]
| BUD/FORM | FORM | Total | |
|---|---|---|---|
| (n = 407) | (n = 403) | (n = 810) | |
| Male, n (%) | 262 (64.4) | 229 (56.8) | 491 (60.6) |
| Age, years (range) | 63.8 (40–86) | 62.5 (40–87) | 63.2 (40–87) |
| Pre-BD FEV1, % predicted | 33.0 (10.5) | 32.4 (10.1) | 32.7 (10.3) |
| Post-BD FEV1, % predicted | 37.9 (11.8) | 37.5 (12.4) | 37.7 (12.1) |
| Pre-BD FEV1/FVC ratio, % | 45.9 (11.3) | 46.1 (11.1) | 46.0 (11.2) |
| Smoking history | |||
| Current smokers, n (%) | 138 (33.9) | 154 (38.2) | 292 (36.0) |
| Pack-years (range) | 52.6 (10–200) | 52.2 (10–258) | 52.4 (10–258) |
| Most common COPD medications before run-in, n (%) | |||
| β2-adrenergic agonists (SABA/LABA) | 320 (78.6) | 321 (79.7) | 641 (79.1) |
| Adrenergics/other drugs for obstructive airway diseases | 198 (48.6) | 196 (48.6) | 394 (48.6) |
| Long-acting muscarinic antagonist | 123 (30.2) | 109 (27.0) | 232 (28.6) |
| Inhaled corticosteroids | 108 (26.5) | 117 (29.0) | 225 (27.8) |
| No. of exacerbations in the past 12 months, n (%) | |||
| 1 | 244 (60.0) | 234 (58.1) | 478 (59.0) |
| 2 | 95 (23.3) | 99 (24.6) | 194 (24.0) |
| 3 | 36 (8.8) | 38 (9.4) | 74 (9.1) |
| 4 | 22 (5.4) | 19 (4.7) | 41 (5.1) |
| ≥ 5 | 10 (2.5) | 13 (3.2) | 23 (2.8) |
| Mean reliever use, inhalations/daya | 5.8 (4.6) | 6.0 (4.5) | 5.9 (4.6) |
| Patients taking ICS at baseline, n % | 108 (26.5) | 117 (29.0) | 225 (2.8) |
Data shown as mean (±SD), unless otherwise stated. Current smokers include habitual and occasional smokers
BD bronchodilator, BUD budesonide, FEV 1 forced expiratory volume in 1 s, FORM formoterol, FVC forced vital capacity, ICS inhaled corticosteroid, LABA long-acting β2-agonists, SABA short-acting β2-agonists, SD standard deviation
aBaseline: 2-week run-in period